pancreatitis%20-%20chronic
PANCREATITIS - CHRONIC
Chronic pancreatitis develops from irreversible scarring sustained by the pancreas from prolonged inflammation.
Signs and symptoms include abdominal pain that is epigastric in location that radiates to the back and frequently occurs at night or after meals, symptoms of fat, protein & carbohydrates maldigestion that become apparent with advanced chronic pancreatitis and presence of diarrhea.
Chronic pancreatitis results in destruction of alpha and beta cells which gives rise to deficiencies of both insulin and glucagon.

Pancreatitis - Chronic Drug Information

Drug Information

Indication: Peptic ulcer disease associated w/ H pylori.

Indication: Healing of gastric ulcers associated w/ NSAID therapy. Prevention of gastric & duodenal ulcers associated ...

Indication: Healing & maintenance of erosive or ulcerative GERD. Healing of duodenal ulcers. Pathological hypersecreto...

Indication: Active duodenal, benign gastric, stomal & recurrent ulceration, persistent dyspeptic symptoms w/ or w/o ul...

Indication: Reflux disease & associated symptoms. Prevention of gastroduodenal ulcers induced by NSAIDs in patients at...

Indication: 20 mg: Mild GERD & associated symptoms eg, heartburn, acid regurgitation, pain on swallowing. Long-term ma...

Dosage: Duodenal & benign gastric ulcers 20 mg once daily for 4-8 wk. Dose may be increased to 40 mg once daily in

Indication: Benign gastric & duodenal ulcer, GERD, Zollinger-Ellison syndrome, H pylori eradication.

Indication: Duodenal & benign gastric ulcer, H pylori-associated peptic ulcer, reflux oesophagitis, Zollinger-Ellison ...

1  /  7
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 3 days ago
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.